New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePEG-MGF vs MK-677 (Ibutamoren)

PEG-MGF vs MK-677 (Ibutamoren)

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
PEG-MGF
Growth Hormone Peptides
MK-677 (Ibutamoren)
Summary
PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
Half-Life
~3 days (due to PEGylation)
24 hours
Admin Route
SubQ
Oral
Research
Typical Dose
200–400 mcg
10–25 mg
Frequency
2–3x per week
Once daily
Key Benefits
  • Extended half-life (~3 days) vs native MGF (minutes)
  • Systemic muscle satellite cell activation via subcutaneous injection
  • Promotes muscle fiber repair and hypertrophy throughout the body
  • Enhanced recovery from intense training or muscle injury
  • Synergistic with IGF-1 LR3 and growth hormone peptides
  • Useful in sarcopenia, post-injury recovery, and athletic performance
  • Single injection provides multi-day anabolic signaling
  • Increases lean muscle mass
  • Enhances bone density
  • Improves sleep quality and REM sleep
  • Accelerates recovery from training
  • Increases appetite
  • May improve skin elasticity and appearance
  • Supports fat loss while maintaining muscle
  • Oral administration — no injections required
  • 24-hour half-life allows once-daily dosing
Side Effects
  • Water retention and localized swelling
  • Potential hypoglycemia at high doses
  • Theoretical cancer growth risk (growth factor)
  • Injection site reactions
  • +1 more
  • Increased appetite (significant in some users)
  • Water retention and puffiness
  • Elevated blood glucose / insulin resistance (monitor in diabetics)
  • Lethargy initially
  • +2 more
Stacks With